Belsomra Compassionate Use and Expanded Access: What Patients Need to Know in 2026

What "Compassionate Use" Actually Means for an Approved Drug Like Belsomra

Compassionate use, formally called expanded access by the FDA, applies to investigational drugs not yet approved for commercial sale. FDA expanded access regulations under 21 CFR Part 312 allow seriously ill patients to receive unapproved therapies when no comparable alternatives exist. [1]

Belsomra received full FDA approval in August 2014 for adults with insomnia characterized by difficulty with sleep onset or sleep maintenance. [2] Because the drug is commercially available, the traditional expanded-access pathway does not apply to most patients seeking it.

When Expanded Access Could Still Be Relevant

There is one narrow scenario where an expanded-access request might make clinical sense: a patient enrolled in a Merck-sponsored trial of suvorexant for an off-label indication (such as delirium prevention in ICU patients or Alzheimer-related insomnia) who responds well and wants continued access after the trial closes. In that situation, a physician can submit an individual patient expanded-access request to the FDA through Form FDA 3926. [3]

The FDA received 1,439 individual expanded-access requests in fiscal year 2023 and approved the vast majority within days. [4] Response time for non-emergency individual requests is typically within 30 days under 21 CFR 312.310. [1]

Suvorexant in ICU and Alzheimer Trials

Suvorexant has been studied beyond its label. A randomized controlled trial published in JAMA Internal Medicine (N=100) found that suvorexant 15 mg reduced delirium incidence from 30% to 14% compared with placebo in mechanically ventilated ICU patients (P<0.05). [5] Patients in such trials who benefit may qualify for continued post-trial access via Merck's medical affairs team or through a formal expanded-access submission.

A separate 4-week trial in patients with Alzheimer's disease (N=285) published in the Annals of Neurology showed suvorexant 10 to 20 mg significantly improved total sleep time versus placebo without worsening cognition. [6] Participants in Alzheimer trials represent the population most likely to encounter a genuine expanded-access need once a specific investigational protocol closes.

How Belsomra Works and Why Cost Becomes the Real Access Barrier

Suvorexant blocks both orexin-A and orexin-B receptors (OX1R and OX2R), suppressing the wake-promoting signal rather than broadly sedating the central nervous system. [7] This mechanism differs from benzodiazepines and Z-drugs, which act on GABA-A receptors and carry higher dependency risk. [8]

Clinical Efficacy at Approved Doses

In the key Phase 3 trials (combined N=3,017), suvorexant 20 mg reduced subjective time to sleep onset by 22 minutes and wake-after-sleep-onset by 28 minutes compared with placebo at 3 months. [9] Patients taking 15 mg saw smaller but still statistically significant reductions. The drug was studied for up to 12 months with no evidence of rebound insomnia on discontinuation, a key advantage over older agents. [9]

The Price Problem

Belsomra's retail price sits at roughly USD 380 per 30 tablets at major US pharmacies as of early 2026. No generic suvorexant is available in the United States yet, though Merck's composition-of-matter patent expires in 2023 and several Paragraph IV ANDA filings are under FDA review. [10] Once a generic clears, prices could fall by 80% or more based on historical patterns seen with other Schedule IV hypnotics.

Until then, cost is the primary barrier. The sections below cover every legitimate strategy to reduce or eliminate that cost.

Merck's Patient Assistance Program: Merck Helps

Merck operates a patient assistance program called Merck Helps that provides Belsomra at no cost to qualifying patients. The program is income-based.

Eligibility Criteria

To qualify for Merck Helps in 2026, a patient generally must:

• Be a US resident without adequate prescription coverage for suvorexant
• Have a household income at or below 400% of the federal poverty level (approximately USD 60,240 for a single individual in 2026)
• Have a valid prescription from a licensed US prescriber

Applications are submitted at merck.com/patient-assistance-program or by calling 1-800-727-5400. Physicians may apply on behalf of patients directly from the office. Processing typically takes 2 to 4 weeks for first-time applicants.

Bridge Supply While the Application Processes

Merck provides a 30-day bridge supply in some cases while the full application is reviewed. Ask the Merck Helps representative explicitly about bridge supply availability when calling, as this policy can change.

Manufacturer Coupons and Co-Pay Cards

Merck has offered a co-pay savings card for commercially insured patients that reduces the out-of-pocket cost to as low as USD 30 per 30-tablet prescription. [11] These cards are not available to Medicare or Medicaid beneficiaries under federal anti-kickback rules.

Check belsomra.com for the current offer before each refill. Co-pay card programs are renewed annually and the terms change, so a card that worked last quarter may have different limits today.

The card typically caps annual savings at USD 1,200 to USD 1,800 depending on the current program year. If a patient uses the card every month, they effectively pay roughly USD 30 to 75 per fill instead of USD 380.

HSA and FSA Payment for Belsomra

Yes, Belsomra is eligible for payment with Health Savings Account (HSA) and Flexible Spending Account (FSA) funds. The IRS defines qualified medical expenses under Section 213(d) to include prescription drugs. [12] Suvorexant is a Schedule IV prescription drug, so any fill with a valid prescription qualifies.

Practical Steps

1. Obtain a written prescription from your physician.
2. Pay at the pharmacy using your HSA or FSA debit card, or pay out of pocket and submit the receipt for reimbursement.
3. Keep the pharmacy receipt and the prescription label as documentation in case of IRS audit.

Using pre-tax HSA or FSA dollars effectively reduces the real cost by your marginal tax rate. A patient in the 22% federal bracket paying USD 380 per month saves approximately USD 84 per fill through this mechanism alone.

FSA funds are subject to the use-or-lose rule under 26 USC 125 unless the plan includes a carryover or grace period. [13] HSA funds roll over indefinitely. For patients whose insurer denies Belsomra coverage, combining HSA/FSA payment with a GoodRx or NeedyMeds discount code can reduce cost further.

Pharmacy Discount Programs and GoodRx

GoodRx, NeedyMeds, and RxSaver publish negotiated cash prices that are sometimes lower than insurance co-pays, particularly for non-preferred brand drugs. As of early 2026, GoodRx prices for suvorexant 20 mg (30 tablets) range from USD 280 to USD 370 depending on the pharmacy and ZIP code.

These programs work by presenting a discount card or code at the pharmacy counter. They are compatible with HSA/FSA payment: pay with the discount code, then pay using the HSA/FSA card.

State pharmaceutical assistance programs (SPAPs) offer additional help in states including New Jersey, Pennsylvania, and Connecticut for residents over 65 or with low incomes. Check your state health department's website for current SPAP eligibility thresholds.

Insurance Coverage Strategies: Prior Authorization and Appeals

Most commercial plans classify Belsomra as a Tier 3 or Tier 4 non-preferred brand. Prior authorization is required by the majority of PBMs.

What Prior Authorization Requires

A PA request for suvorexant typically requires documentation that the patient has tried and failed at least one generic alternative. Commonly required step-therapy agents include:

• Doxepin 3 mg or 6 mg (generic, approximately USD 15/month) [14]
• Zolpidem IR or ER (generic)
• Trazodone (off-label, generic)

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for the pharmacologic treatment of chronic insomnia in adults states: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment)." [15] That guideline recommendation supports the medical necessity argument in a PA or appeal letter.

Writing an Effective Appeal

If a PA is denied, a physician can write a letter of medical necessity citing:

1. Prior failed trials of step-therapy agents with documentation of adverse effects or lack of efficacy
2. The AASM 2017 guideline recommendation for suvorexant [15]
3. Clinical rationale for why generic alternatives are contraindicated (e.g., doxepin is contraindicated in patients with untreated angle-closure glaucoma or urinary retention)

Appeals succeed at a higher rate when they include objective data, such as sleep diary entries or actigraphy results, not just a physician's subjective assessment.

Therapeutic Alternatives When Belsomra Remains Unaffordable

If every cost-reduction strategy fails, several alternatives share suvorexant's orexin-blocking mechanism or offer a similar risk profile.

Lemborexant (Dayvigo)

Lemborexant is the other FDA-approved dual orexin receptor antagonist, approved in December 2019. [16] In the SUNRISE-2 trial (N=949, 12 months), lemborexant 5 mg and 10 mg significantly improved sleep onset and maintenance versus placebo with a similar next-morning somnolence profile to suvorexant. [17] Its patent timeline differs from suvorexant's, so pricing and formulary tier may vary by plan.

Low-Dose Doxepin

The FDA approved doxepin 3 mg and 6 mg specifically for insomnia in 2010. [18] At these doses, doxepin acts purely as a histamine H1 antagonist with negligible anticholinergic effects. A 4-week randomized trial (N=240) showed doxepin 6 mg reduced wake-after-sleep-onset by 32 minutes versus placebo (P<0.001). [19] Generic doxepin at these doses costs under USD 20 per month at most pharmacies.

Cognitive Behavioral Therapy for Insomnia

The AASM and the American College of Physicians both recommend Cognitive Behavioral Therapy for Insomnia (CBT-I) as first-line treatment before pharmacotherapy. [20] A meta-analysis of 87 randomized controlled trials (N=6,873) published in JAMA Psychiatry found CBT-I produced a standardized mean improvement in sleep efficiency of 0.98 compared with control. [21] Digital CBT-I platforms (such as Sleepio or Somryst, the FDA-authorized prescription digital therapeutic) are covered by some commercial payers and Medicare Advantage plans.

The HealthRX Access Decision Framework for Suvorexant

When a patient cannot access Belsomra at standard retail cost, the HealthRX medical team uses a structured four-step approach:

Step 1. Confirm insurance status and tier placement. Call the PBM to get the exact PA criteria in writing before prescribing. This saves weeks of back-and-forth.

Step 2. Apply for Merck Helps if uninsured or underinsured. Submit the application the same day as the prescription is written. Request a bridge supply.

Step 3. Use a co-pay card plus HSA/FSA if commercially insured. Stack the Merck savings card with HSA/FSA payment to minimize out-of-pocket cost while the PA processes.

Step 4. Consider lemborexant or doxepin 6 mg as a formulary alternative. If step therapy is required anyway, a 4-week trial of generic doxepin 6 mg documents the required prior failure and opens the door to suvorexant coverage, while also treating the patient's insomnia during the waiting period.

This sequence minimizes time-to-treatment and maximizes the likelihood of eventual insurance coverage for suvorexant.

Off-Label Use and Expanded Access for Specific Populations

ICU Delirium Prevention

The JAMA Internal Medicine trial cited above (N=100) used suvorexant 15 mg nightly in mechanically ventilated patients. [5] This remains off-label. If a hospitalist or intensivist wants to use suvorexant for delirium prevention, no PA is typically required for inpatient formulary use, but the prescriber should document the clinical rationale and reference the published evidence.

Alzheimer's Disease and Dementia-Related Insomnia

The FDA label does not restrict suvorexant to cognitively intact patients. The Annals of Neurology trial (N=285) demonstrated safety and efficacy in mild-to-moderate Alzheimer's disease with no worsening on the MMSE at 4 weeks. [6] Physicians prescribing suvorexant in this population should start at 10 mg given the higher sensitivity to next-day sedation in older adults, per the prescribing information. [22]

Pediatric Use

Suvorexant has not been studied in patients under 18. The FDA label does not include a pediatric indication. [22] There is no active IND for pediatric expanded access as of mid-2026.

Safety Considerations That Affect Prescribing Decisions

Suvorexant is a Schedule IV controlled substance under the Controlled Substances Act. [23] This classification reflects a low but real potential for misuse and dependence. The prescriber and patient should discuss:

• Next-morning impairment. The FDA added a warning in 2020 about complex sleep behaviors and next-morning driving impairment, particularly at the 20 mg dose. [24] Patients should not drive until they know how suvorexant affects them.
• Drug interactions. CYP3A4 inhibitors (ketoconazole, clarithromycin) can more than double suvorexant exposure. The label recommends reducing the dose to 5 mg in patients on strong CYP3A4 inhibitors. [22]
• Respiratory depression. Unlike benzodiazepines, suvorexant does not appear to cause clinically significant respiratory depression at approved doses in patients with mild-to-moderate COPD, based on a dedicated respiratory safety study. [25]

A 2023 systematic review in the BMJ Open (N=7 trials, 4,328 participants) found suvorexant produced a relative risk of next-day somnolence of 2.1 (95% CI 1.6 to 2.7) versus placebo at 20 mg, lower than the relative risk seen with benzodiazepine receptor agonists at equipotent doses. [26]